DrugDashboards

Ethacrynic Acid

Ethacrynic Acid · ETHACRYNIC ACID 25 mg/1 · Tablet · Oral · Amneal Pharmaceuticals NY LLC

NDC 69238-1126-01 · 100 TABLET in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 30% over the past year, to $0.7836 per unit. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.7836per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$4.22per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$1.67per unitnegotiated price across 1,225 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$0.7836per TABweighted avg manufacturer price $0.3427 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.67per unit
middle half $1.62$2.14 · 1,225 plans · Apr 1, 2026
Est. net of rebates
≈ $1.67
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
22%of plans cover it
tier 4 · prior auth 1% · step therapy 0% · qty limit 68%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$5.00$10.00$15.00Feb 2019Sep 2026$0.7836
44 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$23.51
#90 count
$70.52

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$16,266
115 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

8Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • price down 24% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for ethacrynic acid (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA208805
TE code
AB
Approval date
May 8, 2018
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ethacrynic Acid (Tablet)

LabelerStrengthFirst seenLast seen
Amneal Pharmaceuticals NY LLCETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Bausch Health US, LLCETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Edenbridge Pharmaceuticals LLC.ETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.ETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Oceanside PharmaceuticalsETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
ScieGen Pharmaceuticals IncETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
St. Mary's Medical Park PharmacyETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Trupharma LlcETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026
Upsher-Smith Laboratories, LLCETHACRYNIC ACID 25 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Ethacrynic Acid — NDC 69238-1126-01," retrieved September 3, 2026, https://drugdashboards.com/drug/69238112601.

Free to cite with attribution — see how the data is put together.